Health Canada approves risankizumab for children with plaque psoriasis
Health Canada has expanded risankizumab’s Canadian indication to children aged 6 to under 18 with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The approval changes the product label; coverage decisions remain separate.
Oct 23, 2026 · 3 min read Read briefing